Millicent Embry
Sutro Biopharma (United States)(US)
Publications by Year
Research Areas
Synthesis and biological activity, HER2/EGFR in Cancer Research, Estrogen and related hormone effects, Growth Hormone and Insulin-like Growth Factors, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response(2015)1,424 cited
- Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.(2001)
- → CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo(2007)149 cited
- → Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer(2012)73 cited
- → CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice(2006)66 cited
- → Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001(2018)52 cited
- → Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001(2023)13 cited
- → Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin's Lymphoma (NHL)(2016)10 cited
- → The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death(2025)4 cited
- → Abstract 1695: Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML(2015)2 cited